## Clinical Diagnosis and Initial Management **Key Point:** In seropositive myasthenia gravis (MG) with confirmed anti-AChR antibodies, the diagnosis is established and symptomatic management with acetylcholinesterase inhibitors should begin immediately, followed by definitive therapy (thymectomy). ### Rationale for Correct Answer This patient has **seropositive generalized MG** (positive anti-AChR antibodies + systemic symptoms). The management pathway is: 1. **Symptomatic relief:** Pyridostigmine inhibits acetylcholinesterase, prolonging acetylcholine (ACh) dwell time at the neuromuscular junction and improving neuromuscular transmission. 2. **Definitive therapy:** Thymectomy is indicated in all seropositive MG patients (especially those <60 years with generalized disease) because 10–15% have thymoma and 80% show thymic abnormalities. 3. **Timeline:** Start pyridostigmine immediately for symptomatic control while arranging thymectomy (weeks to months). **High-Yield:** Anti-AChR seropositivity = thymectomy is indicated. Do not delay with further diagnostic testing. ### Why Thymectomy? The thymus is the source of autoreactive B and T cells producing anti-AChR antibodies. Thymectomy leads to: - Remission in ~30% of patients - Significant improvement in 50% within 5 years - Reduced antibody titers [cite:Harrison 21e Ch 382] ## Differential Management Approaches | Scenario | First-Line Action | |----------|-------------------| | **Seropositive MG (this case)** | Pyridostigmine + thymectomy | | **Seronegative MG** | Pyridostigmine ± immunosuppression (no thymectomy benefit proven) | | **Myasthenic crisis** | IVIG or plasma exchange + mechanical ventilation | | **Diagnostic uncertainty** | Edrophonium test (if anti-AChR negative) | **Clinical Pearl:** Pyridostigmine dosing starts at 60 mg TID and is titrated by response; overdose causes cholinergic crisis (miosis, bronchospasm, muscle fasciculations).
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.